...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Why now?

Ok, offer is in.  Let's see what happens.  I did half at below bid/ask (.30) and half at .45.  Lets see what happens.  As that will total about 50% of the daily trading volume I don't hold out much hope.  I also heard about the $20 potential offer through a third party but who knows.  Maybe Dutchfell and I have the same friend?  GLTA

Share
New Message
Please login to post a reply